Company ProfilePremium

Lung Kee (Bermuda) Holdings Limited

Company Profile Analysis

Ticker: 0255.HK龍記集團控股有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Lung Kee (Bermuda) Holdings Limited - Company showcase

Year Founded & Workforce

1975

2,700 Employees

Lung Kee (Bermuda) Holdings Limited logo

Lung Kee (Bermuda) Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Lung Kee (Bermuda) Holdings Limited Overview

MetricFY2022FY2023FY2024FY2025H1 2026
Employees (approx, year-end)2,9002,9002,9002,8002,700

The figure of 2,900 comes from the company's irasia corporate profile updated 26 June 2024. The FY2022, FY2023 and FY2025 figures come from the respective final results announcements; the H1 2026 figure comes from the 2026 interim results.

Lung Kee Group is a Hong Kong-headquartered, family-controlled precision-metal manufacturer. It is one of the world's largest makers of mould bases: the machined steel frames, plates and components that toolmakers turn into injection, die-casting and stamping moulds. The company describes itself as the leader of China's mould base industry. Its LKM brand is a de facto standard among Asian mould makers, and the company was the first in Hong Kong to bring CNC machining centres into mould base production. Plants in mainland China, Japan and Malaysia serve about 2,700 staff and thousands of tool shops. Through them, Lung Kee's demand is tied to the capital-goods cycles of consumer electronics, home appliances, automotive (including new-energy vehicles), toys, packaging and medical products. The business is single-segment, about 86% PRC-delivered, and debt-free. It holds about HK$650m of cash, and its investment case now rests on balance-sheet strength and high payouts more than on earnings, after three consecutive loss-making years.


Company's own description (latest filings)

In its FY2025 final results (20 Mar 2026) and H1 2026 interim results (21 Aug 2026), the company describes itself as principally engaged in the manufacturing and marketing of mould bases and related products. Key disclosed points:

  • It manufactures and sells directly to customers. Revenue is recognised at a point in time, when goods are delivered.

  • It grants trade credit of 30 to 90 days.

  • All contracts have an expected duration of one year or less.

  • The chief operating decision maker (the executive directors) reviews the group as one aggregated operating segment.

  • The company says its customer base is very wide, covering Asia, Europe and America. No single customer accounted for 10% or more of revenue in FY2022 through FY2025, or in H1 2025 and H1 2026.

The irasia corporate profile (updated 26 June 2024) adds:

  • The company calls itself one of the world's largest mould base manufacturers and the leader of China's mould base industry.

  • It distributes quality tool-steel brands, including DAIDO, alongside its own "LKM Special Steel".

  • Its facilities in China, Japan and Malaysia cover about 550,000 square metres.

The holding company itself provides investment holding and corporate management services. The group also holds investment properties in Hong Kong, carried at HK$146.5m at 30 June 2026.

What a mould base is and why it matters

A mould base is, in effect, a semi-finished mould. It is the precision-machined steel structure (clamping plates, cavity and core plates, ejector plates, support pillars, guide pins and bushes) into which a toolmaker machines the part-specific cavity. Mould makers increasingly outsource the base to specialist suppliers. This cuts lead times, reduces their own capital spending on heavy machining equipment, and avoids stocking raw steel. Standardised bases can be ordered from a catalogue with transparent pricing, which reduces engineering effort. Lung Kee has publicly promoted this argument, for example in a trade-press interview aimed at Vietnamese mould makers.

Business model and revenue model

Revenue streamNatureDisclosure status
Standard mould basesCatalogue product, made to stock or to short lead times; volume-drivenRevenue split not publicly disclosed
Custom-made mould basesMade to order to customer drawings; higher machining content—
High-precision interchangeable plates / precision platesPlates machined to tight tolerances for interchangeability—
Mould components and standard insertsGuide pins, bushes, ejector components, inserts—
Tool steel trading and processingDistribution of third-party (DAIDO) and own-brand "LKM Special Steel" plastic, hot-work and cold-work steels; cut-to-size processing—
Machining servicesAdditional machining on bases and plates. Management cited higher machining content as a driver of margin improvement in FY2025 and H1 2025—
Rental income (non-core)Hong Kong investment propertiesHK$3.2m net (FY2025); HK$1.5m (H1 2026)

The model is about 100% product sales, with machining value-add built into product pricing. There is no subscription or licensing income. The group's economics are those of a capital-intensive, high-fixed-cost metal fabricator:

  • Raw materials and consumables (mainly mould steel) were 35.7% of revenue in FY2025.

  • Employee costs were 31.9% of revenue in FY2025.

  • Depreciation was 12.0% of revenue in FY2025.

Value-chain position

Lung Kee sits in the middle of the tooling value chain:

Upstream: special steel mills and distributors (Japanese, European and Chinese mould steel producers).

Lung Kee: turns steel into precision bases, plates and components. It also distributes tool steel, which gives it purchasing scale and lets it offer customers a "one-stop" service.

Downstream customers: independent mould and die makers, and the in-house tool rooms of manufacturers.

End markets: the products eventually moulded or die-cast with those tools.

Customer types and end-markets

End-marketManagement commentary (paraphrased, with source)
Home appliancesWeak because of China's property slump (FY2022, FY2023, FY2025); supported by trade-in subsidies (FY2025, H1 2026)
Household furniture productsWeak because of the property slump (FY2022, FY2023)
Automotive, incl. new-energy vehicles (NEV)NEV demand a bright spot (FY2023); both NEV and traditional fuel vehicles expected to progress (FY2023 outlook)
Consumer and high-tech electronicsExpected recovery (FY2022 and FY2023 outlooks); hurt by US tariffs and technology controls (FY2025, H1 2026)
Food containers / packagingExpected to keep growing on an environmental focus (FY2025 outlook)
Toys, including "trendy toys"Growth momentum from design and branding (FY2025 outlook)
Medical and pandemic productsStable in 2022; expected to shrink as the pandemic receded (FY2022 outlook)
AI products, robotics, "low-altitude economy"Government-backed new growth areas (FY2025 and H1 2026 outlooks)

Customers are mould makers rather than end-OEMs, which is why customer concentration is very low. Demand ultimately follows new-model and new-product launch activity (new moulds) in the end markets named in management commentary across FY2022 to H1 2026:

Independent characterisation

Lung Kee is a scale leader in a fragmented, commoditising niche. Its moat comes from:

  • brand recognition (LKM as a standard reference);

  • breadth of catalogue;

  • delivery speed from distributed plants;

  • steel-purchasing scale.

Its revenue fell 42% from FY2021 (HK$2,273m) to FY2025 (HK$1,320m). That decline reflects three forces:

  • the cyclical downturn in Chinese consumer-durables tooling demand;

  • export pressure from US-China trade friction and the relocation of supply chains to Southeast Asia and India;

  • price "involution" (destructive price competition) among Chinese mould base makers.

Management's response has been defensive: holding prices, raising machining content, automating to cut headcount, and cutting capex sharply. Meanwhile it has paid out cash above earnings, funded by a debt-free balance sheet. The company has made no transformational move: no acquisitions, no new segment, and no offshore production expansion has been disclosed in the last five years.

Strategy

Stated strategy themes (latest annual and interim results)

ThemeDescription (paraphrased)First / latest mention
Move up the value chainShift toward high-quality, high-tech production; pursue orders with high machining content to gain share and revenueFY2023 / FY2025
Automation and unmanned productionExpand automated production lines and adopt unmanned technologies and equipment to reduce reliance on manpower and lift processing capability, speed and qualityFY2022 / FY2025
Plastic and die-casting mould capabilityDevelop plastic and die-casting technology to improve processing capability, efficiency and product quality, in line with market trends (NEV die-casting, electronics)FY2025 / H1 2026
"Intelligent, advanced and efficient" productionUse smart production modes to improve overall processing capabilityH1 2026
Cost and raw-material disciplineMonitor raw-material prices and operating costs closely to protect margins and reduce operational riskEvery year
Market diversificationStrengthen the sales team; expand in the Chinese domestic market and in overseas and Southeast Asian markets; follow customers into ASEAN, India and Belt and Road marketsFY2023 / H1 2026
Align with Chinese policy demandTarget sectors supported by state stimulus: trade-in programmes (appliances, autos), NEVs, high-tech electronics, smart appliances, AI/robotics, low-altitude economyFY2023 / H1 2026
Prudent financeKeep conservative financial management and sufficient resources; no borrowingsEvery year
Cautious stanceAdopt a cautious, pragmatic approach to manage risk and aim for sustainable development and reasonable growthH1 2026

Lung Kee does not hold investor days or publish formal strategic plans. Strategy is articulated in the "Prospects" section of each results announcement. The recurring themes from FY2023 to H1 2026 are paraphrased below.

The FY2025 results close by restating the corporate ethos of "keeping abreast with time, keeping exploration and innovation", with the stated aim of returning to profit.

Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

InitiativeStatusDisclosure detail
Automation / unmanned machining roll-outOngoingQualitative only; no capex budget, line count or headcount target disclosed. Capex fell to HK$35.5m (FY2024) and HK$40.0m (FY2025) from HK$201m (FY2021), suggesting the main automation wave is complete
Machining-content upgrade (pricing and mix)Ongoing; cited as a margin driverRaw-material ratio improved to 35.7% (FY2025) and 34.3% (H1 2026)
Plastic and die-casting mould technology developmentOngoingNo investment figure disclosed
Cost reductionOngoingOther expenses −16.6% (FY2025) and −24.2% (H1 2026); employee costs −5.9% in H1 2026; headcount −100 in H1 2026
Special dividend return of capitalExecutedHK12 cents special dividend for FY2024 (HK$75.8m)
Share option grants (talent retention)ExecutedOptions granted 27 Sep 2024; small share issuance (HK$2.84m proceeds in FY2025)
Governance: registrar change; board refreshExecutedAppleby appointed Bermuda registrar (31 Dec 2024); board reduced to nine

New business launches, partnerships, platform investments: none disclosed.

Formal ESG targets: none disclosed in the sources reviewed.

Cost programmes with quantified targets: not publicly disclosed.

Medium-term financial targets and guidance

The company provides no quantitative guidance or medium-term financial targets. Its forward-looking statements are qualitative. The H1 2026 outlook describes a harsh market outlook with multiple downside risks. The company uses profit warnings and alerts (Listing Rule 13.09 inside-information announcements) as its de facto guidance mechanism, for example on 6 Jan 2023, 5 Jan 2024, 6 Jan 2025, Jul 2025, 5 Jan 2026 and 7 Jul 2026.

Products & Services

All products sit within the single segment. Lung Kee does not publish revenue by product line, pricing or launch dates, so those fields are marked accordingly.

Product Portfolio

Product / serviceDescriptionKey capabilities / specificationsTarget customerLaunch / latest versionPricing modelFlagship / notes

Standard mould bases

Catalogue mould bases in standardised sizes and configurations (plates, pillars, bushes, ejector system)

Interchangeability; short lead time; LKM catalogue standards widely adopted in China ("synonymous with domestic mould standards", per company profile)

Injection-mould makers in consumer electronics, appliances, toys and packaging

Long-standing core product; latest version not disclosed

Catalogue price lists (price transparency cited by LKM)

LKM standard series; capacity historically above 55,000 complete sets per month (trade press interview, date not specified)

Custom-made (tailor-made) mould bases

Bases machined to customer drawings, including large and medium bases for automotive and appliance moulds

Large-size assembly; automotive-grade bases; higher machining content

Automotive, appliance and die-casting mould makers

Expanded in the 2000s (large automotive bases cited in FY2002/03)

Quote-based

Management focus on "orders with high machining content" (FY2025 outlook)

High-precision interchangeable plates / precision plates

Plates ground and machined to tight tolerances for direct interchange

Precision grinding and CNC machining

Precision mould makers (electronics, medical)

—

Catalogue / quote

Historically produced at the Guangzhou high-precision plant (FY2003)

Mould components

Guide pins, bushes, ejector pins and sleeves, locating parts

Standardised parts compatible with LKM bases

All mould makers

Developed at Dongguan from the early 2000s

Catalogue

Part of the "one-stop" offer

Standard mould inserts

Pre-machined insert blocks

Standardised dimensions

Mould makers

—

Catalogue

Listed in Morningstar business description

Tool steel: plastic mould steel

Pre-hardened and through-hardened plastic mould steels

Supplied as blocks or cut-to-size

Mould makers

Ongoing

Per-kg / per-block pricing (not disclosed)

Distribution of DAIDO (Japan); historically also ASSAB

Tool steel: hot-work and cold-work steel

Steels for die-casting dies and stamping dies

Cut-to-size, machining

Die-casting and stamping tool makers

Ongoing

—

"LKM Special Steel" own brand

Machining services

Additional CNC machining (cavity roughing, drilling, milling) on bases and plates

Automated and unmanned machining lines (FY2023–FY2025 outlooks)

Mould makers outsourcing machining

Rising share cited in FY2025 and H1 2025

Quote-based

Cited as a margin driver in FY2025

Plastic and die-casting mould technology

Development of processing capability for plastic and die-casting moulds

Production efficiency and quality upgrades

Die-casting customers (NEV structural parts, electronics housings)

Strategic focus in FY2025 and H1 2026 outlooks

—

Management's stated technology priority

Heat treatment, PVD coating, repair-welding (historic)

Vacuum heat treatment, PVD coating and mould repair services

Value-added services

Mould makers

Introduced in the early 2000s at Dongguan

—

Current status not re-confirmed in recent filings

Hot runner products (historic R&D)

Hot runner systems development

Early-stage at Dongguan in 2003

Mould makers

2003 (development stage)

—

No mention in recent filings; status not publicly disclosed

“—” = not publicly disclosed.

Financial Narrative

Methodology note

Lung Kee presents its income statement by nature of expense. It does not disclose cost of sales, gross profit or operating profit as separate lines. To give a consistent five-year view, the following derived measures are used. Each is computed from audited line items and is not a company-reported figure.

These derived figures include investment-property fair-value changes and other gains and losses, which are reported within pre-tax profit.

Third-party data providers compute gross margin differently. For example, S&P Global shows a FY2025 gross margin of about 61.5% using only materials as cost of revenue. Their figures are not comparable with the derived measures below.

Income statement

[Sources: FY2022 Final Results (FY2021 and FY2022 data); FY2023 Final Results; FY2025 Final Results (FY2024 and FY2025 data). Diluted EPS for FY2021 and FY2022 was not presented because there were no dilutive shares; the basic figure is shown. FY2021 YoY growth uses FY2020 revenue of about HK$2,064.9m from a secondary source (TipRanks).]

Dividend composition by year (HK cents):

  • FY2021: interim 15 + final 20

  • FY2022: interim 6 + final 6

  • FY2023: interim 5 + final 5

  • FY2024: interim 5 + final 6 + special 12

  • FY2025: interim 8 + final 12

  • FY2026 interim: 8 (declared 21 Aug 2026)

Margins

Revenue CAGR FY2021–FY2025 (four years): −12.7% per year (HK$2,273.4m to HK$1,319.9m).

Commentary: income statement trends, inflections and drivers

FY2021 peak and FY2022 collapse: FY2021 was a cyclical high. Post-COVID restocking pushed revenue up 10.1% to HK$2,273m and net profit to HK$228m. In FY2022, revenue fell 29.6% as repeated COVID lockdowns in China, a collapsing property market (which cut demand for appliances and furniture) and weaker exports shrank market orders. Management noted that the second half of 2022 was worse than the first. The raw-material ratio rose from 36.1% to 39.9%, partly because high-cost steel bought earlier turned over slowly. Net profit fell 93% to HK$15.8m. [FY2022 Final Results]

FY2023 trough: In FY2023 the company cut selling prices to win orders in a shrinking market. Revenue fell a further 9.5%, but raw-material cost fell only 0.5%, so the ratio jumped to 43.8%. Depreciation rose 6.9% after years of automation capex. The result was a HK$112.6m pre-tax loss, softened by a HK$40.2m tax credit (including HK$6.0m of prior-year overprovisions) to a HK$72.4m net loss. [FY2023 Final Results]

FY2024 partial recovery: Revenue rose 7.2% and the raw-material ratio fell back to 38.7%. The loss narrowed to HK$13.7m.

FY2025 renewed decline: Revenue fell 15.0% as aggregate orders dropped sharply. The company said it held pricing better and that machining services increased, which lowered the raw-material ratio to 35.7%, the best in five years. However, fixed costs did not fall in line:

  • employee costs were down only 1.5%;

  • PPE depreciation was down 5.6%;

  • other expenses were down 16.6%.

The net loss widened to HK$22.6m. That figure includes a HK$10.2m investment-property revaluation loss and is net of a HK$12.9m gain on disposal of PPE. [FY2025 Final Results]

The core issue is operating leverage: Employee costs have stayed at roughly HK$410–430m since FY2022 while revenue has drifted down. Employee cost rose from 25% to 32% of revenue, which absorbed all of the improvement in material margin. The derived gross margin of about 14% in FY2024 and FY2025 is roughly half the FY2021 level.

H1 2026: Revenue fell 17.5% to HK$568.3m. The raw-material ratio improved further to 34.3%. Employee costs fell 5.9% and other expenses fell 24.2%. Even so, the pre-tax loss widened to HK$14.2m, from HK$1.9m in H1 2025. An HK$9.0m PPE disposal gain and a HK$3.8m tax credit limited the net loss to HK$10.4m. [H1 2026 Interim Results]

Balance sheet

[Sources: FY2022, FY2023 and FY2025 Final Results. Book value per share uses 631.68m shares for FY2021–FY2024 and 633.89m for FY2025 (share capital HK$63.389m at HK$0.10 par).]

Latest balance sheet (30 Jun 2026):

  • Total assets HK$1,756.7m; equity HK$1,506.8m.

  • Cash HK$649.7m; no borrowings; lease liabilities HK$2.8m.

  • Inventories HK$302.1m; PPE HK$390.0m; investment properties HK$146.5m.

  • Working capital HK$914.5m.

[H1 2026 Interim Results]

Commentary. The balance sheet is extremely conservative. The group has carried no bank borrowings in every year reviewed, and cash has been placed in short-term deposits with major banks in Hong Kong and the PRC.

Equity fell by HK$720m between FY2021 and FY2025, from HK$2,271m to HK$1,551m. The drivers were:

  • cumulative dividends of about HK$662m (FY2021–FY2025 cash basis: 208.4 + 164.2 + 69.5 + 63.1 + 164.2);

  • cumulative net losses of HK$109m over FY2023–FY2025;

  • RMB translation losses of HK$136m in FY2022 and HK$44m in FY2023, partly reversed by gains of HK$61m in FY2025 and HK$42m in H1 2026.

Inventories have been run down by HK$302m since FY2022 (from HK$606.9m to HK$302.1m at June 2026), releasing cash. PPE has shrunk by 42% since FY2022 as depreciation (about HK$160m a year) far exceeds capex (about HK$35–40m a year in FY2024 and FY2025). The asset base is therefore deliberately contracting. Shareholders' funds now equal roughly HK$2.38 per share at June 2026, of which about HK$1.02 per share is net cash.

Cash flow

[Sources: Operating cash flow, capex, FCF and working capital are S&P Global Market Intelligence data via StockAnalysis.com (secondary; not cross-checked to the annual report cash flow statement). Dividends recognised as distributions per the final results notes are FY2021 HK$271.6m, FY2022 HK$164.2m, FY2023 HK$69.5m, FY2024 HK$63.2m and FY2025 HK$164.2m. The FY2021 difference from cash paid (HK$208.4m) reflects timing of payment and scrip/dividend-payable movements. Buybacks are confirmed nil by "no purchase, sale or redemption" statements in the FY2022, FY2023 and FY2025 results, and by an unchanged weighted share count of 631,677,303 in FY2021–FY2024.]

Commentary. Despite accounting losses, Lung Kee has generated strong free cash flow in FY2024 and FY2025 (HK$191m and HK$168m). The sources are a non-cash depreciation charge of about HK$160m a year, inventory liquidation of about HK$146m over those two years, and capex cut to about a quarter of FY2021 levels. This is a harvest-mode profile.

The heavy automation capex of FY2021–FY2023 (HK$497m cumulative) ended in FY2024. Those investments now feed through depreciation. FY2025 dividends (HK$164m) roughly equalled FY2025 FCF (HK$168m). FCF cannot stay at this level unless inventory release continues or EBITDA recovers.

Ratios

[Derived from audited line items as listed above. Interest coverage is not meaningful given negligible lease interest. ROIC uses an assumed 25% PRC tax rate on derived EBIT.]

Commentary on ratios.

Returns: have been negative for three years. FY2021 shows that through-cycle ROIC of mid-teens is achievable at about HK$2.2–2.3bn of revenue.

Liquidity: is outstanding: a current ratio above 5x and net cash equal to roughly 39% of equity.

Cash conversion cycle: has improved by about 40 days since FY2022, mainly because days inventory fell from 165 to 125. Raw-material inventory is still the dominant working-capital use (HK$338.6m of HK$389.4m inventory at FY2025).

DSO: of about 21 days is very low for an industrial B2B supplier. This reflects tight credit control (30–90 day terms) and a fragmented customer base. Receivables over 90 days were only HK$3.9m at FY2025.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Segment revenue (HKD Mn)

1,449.31,553.21,319.9

Segment revenue YoY growth (%)

-9.57.2-15.0

Segment result: profit (loss) after tax (HKD Mn)

-72.4-13.7-22.6

Segment pre-tax result (HKD Mn)

-112.6-19.4-33.1

Segment pre-tax margin (%)

-7.8-1.2-2.5

Segment net margin (%)

-5.0-0.9-1.7

Contribution to group revenue (%)

100100100

Revenue by Segment

MetricH1 2024H1 2025H1 2026

Segment revenue (HKD Mn)

785.2688.7568.3

Segment loss after tax (HKD Mn)

-23.9-3.6-10.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityLocationFunctionSource

Lung Kee Group Holdings Limited

Bermuda / HK

Listed holding company; corporate management

Filings

Heyuan Longji Metal Products Co., Ltd. (河源龍記金屬製品有限公司)

Heyuan, Guangdong, PRC

Mould base manufacturing

moomoo company profile

Lung Kee Metal Japan Co., Ltd.

Japan

Production and sales in Japan

Trade press (APMEN); moomoo

Supervision International Co., Ltd.

—

Group subsidiary

moomoo company profile

Lung Kee International Limited; Lung Kee Metal Limited

Hong Kong

Historic group companies in which the founders held non-voting/deferred interests (49.99%)

2007 Interim Report

“—” = not publicly disclosed.

Financial Analysis

MeasureDefinition

Gross profit (derived)

Revenue minus "cost of inventories recognised as an expense" (inventory note)

Material margin (derived)

Revenue minus raw materials and consumables used, adjusted for the change in finished goods and WIP

EBIT (derived)

Pre-tax profit plus interest expense on lease liabilities (the group has no bank borrowings)

EBITDA (derived)

EBIT plus depreciation of property, plant and equipment plus depreciation of right-of-use assets

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (HKD Mn)

2,273.41,601.41,449.31,553.21,319.9

Revenue YoY growth (%)

10.1-29.6-9.57.2-15.0

Cost of inventories expensed (HKD Mn)

1,656.21,346.81,336.11,330.51,135.0

Gross profit, derived (HKD Mn)

617.2254.6113.3222.7184.9

Material margin, derived (HKD Mn)

1,451.8962.9814.2951.7848.2

Raw materials as % of revenue, reported (%)

36.139.943.838.735.7

Employee benefits expense (HKD Mn)

571.1436.2411.5427.5421.1

Other expenses (HKD Mn)

435.6369.6362.2383.6319.8

Depreciation, PPE + ROU (HKD Mn)

156.1158.7169.1167.7158.7

Other income, gains and losses (HKD Mn)

39.711.725.814.427.1

Investment property fair-value change (HKD Mn)

-13.06.5-8.5-5.5-10.2

EBITDA, derived (HKD Mn)

472.1180.856.9148.6125.9

EBIT / operating income, derived (HKD Mn)

315.922.0-112.2-19.1-32.8

Interest expense on leases (HKD Mn)

0.50.40.40.30.3

Pre-tax profit (loss) (HKD Mn)

315.521.7-112.6-19.4-33.1

Income tax (expense) credit (HKD Mn)

-87.6-5.940.25.710.5

Net profit (loss) attributable (HKD Mn)

227.815.8-72.4-13.7-22.6

Basic EPS (HK cents)

36.072.50-11.47-2.16-3.58

Diluted EPS (HK cents)

36.072.50-11.47-2.16-3.58

Dividends per share declared for year (HK cents)

3512102320

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin, derived (%)

27.115.97.814.314.0

Material margin (%)

63.960.156.261.364.3

EBITDA margin, derived (%)

20.811.33.99.69.5

Operating (EBIT) margin, derived (%)

13.91.4-7.7-1.2-2.5

Pre-tax margin (%)

13.91.4-7.8-1.2-2.5

Net margin (%)

10.01.0-5.0-0.9-1.7

Employee cost as % of revenue (%)

25.127.228.427.531.9

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (HKD Mn)

2,745.72,301.52,093.01,971.61,817.9

Cash and bank balances (HKD Mn)

833.6536.6428.8546.6588.6

Short-term borrowings (HKD Mn)

00000

Long-term borrowings (HKD Mn)

00000

Lease liabilities, current (HKD Mn)

3.43.63.33.93.5

Lease liabilities, non-current (HKD Mn)

5.66.03.33.90.9

Total debt incl. leases (HKD Mn)

9.09.66.67.84.4

Net debt (negative = net cash) (HKD Mn)

-824.6-527.1-422.2-538.8-584.2

Total equity (HKD Mn)

2,271.31,986.61,798.81,673.51,550.9

Goodwill and intangibles (HKD Mn)

00000

Property, plant and equipment (HKD Mn)

668.5667.7656.0525.2440.6

Investment properties (HKD Mn)

168.5175.0166.5161.0150.8

Inventories (HKD Mn)

604.3606.9530.5460.5389.4

Trade and bills receivables, net (HKD Mn)

159.796.095.698.775.5

Trade and bills payables (HKD Mn)

57.531.435.846.129.3

Current assets (HKD Mn)

1,718.41,294.11,136.41,162.51,102.4

Current liabilities (HKD Mn)

341.0197.7193.3201.5179.7

Working capital (HKD Mn)

1,377.41,096.4943.1961.0922.7

Book value per share (HKD)

3.603.142.852.652.45

Cash Flow and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (HKD Mn)

353.876.977.2226.3208.1

Capital expenditure (HKD Mn)

201.3182.3112.935.540.0

Free cash flow (HKD Mn)

152.4-105.5-35.7190.8168.0

Dividends paid (HKD Mn)

208.4164.269.563.1164.2

Share buybacks (HKD Mn)

00000

Change in working capital (HKD Mn)

-29.2-41.925.083.193.6

FCF margin (%)

6.7-6.6-2.512.312.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, year-end equity (%)

10.00.8-4.0-0.8-1.5

ROA, year-end assets (%)

8.30.7-3.5-0.7-1.2

ROIC, NOPAT at 25% / (equity + debt − cash) (%)

16.41.1-6.1-1.3-2.5

Current ratio (x)

5.046.555.885.776.13

Debt to equity, leases only (%)

0.40.50.40.50.3

Net debt / EBITDA (x)

-1.75-2.92-7.42-3.63-4.64

Interest coverage, EBIT / lease interest (x)

69461-276-68-106

Asset turnover, revenue / year-end assets (x)

0.830.700.690.790.73

Days inventory outstanding (days)

133.2164.5144.9126.3125.2

Days sales outstanding (days)

25.621.924.123.220.9

Days payables outstanding (days)

12.78.59.812.69.4

Cash conversion cycle (days)

146.1177.9159.2136.9136.7

Dividend payout vs FCF (%)

137-156-1953398

Revenue by Region and Revenue by Region (%)

RegionFY2021FY2022FY2023FY2024FY2025

The PRC revenue (HKD Mn)

1,981.51,391.01,258.21,365.11,131.4

Others revenue (HKD Mn)

291.9210.4191.1188.1188.5

Total revenue (HKD Mn)

2,273.41,601.41,449.31,553.21,319.9

The PRC share of revenue (%)

87.286.986.887.985.7

Others share of revenue (%)

12.813.113.212.114.3

Region Margins & Growth (%)

RegionFY2022FY2023FY2024FY2025

The PRC revenue YoY growth (%)

-29.8-9.58.5-17.1

Others revenue YoY growth (%)

-27.9-9.2-1.60.2

Revenue by Region and Region Margins & Growth (%)

RegionH1 2025H1 2026

The PRC revenue (HKD Mn)

594.9477.0

Others revenue (HKD Mn)

93.891.4

The PRC YoY growth (%)

—-19.8

Others YoY growth (%)

—-2.6

Capital Markets

ItemValueSource

Last price

HK$1.365 (8 Oct 2026 close)

S&P Global via StockAnalysis.com

Shares outstanding

634.01m

S&P Global; H1 2026 share capital

Market capitalisation

About HK$865m

Computed

52-week change

−2.04% to 4 Aug 2026 (price HK$1.44 then)

S&P Global via StockAnalysis.com

Approx. 1-year price change (Oct 2025 → Oct 2026)

About +10% (HK$1.24 on 4 Oct 2025 to HK$1.365 on 8 Oct 2026), price only

moomoo (Oct 2025); StockAnalysis (Oct 2026)

Recent trading range

Year range about HK$1.05–1.98 (to Dec 2025); HK$1.75 on 29 Dec 2025

Google Finance

Beta (5Y)

0.24

S&P Global

Average daily volume (20 days)

About 30,000 shares (Aug 2026)

S&P Global

Free float

About 162m shares (about 26%)

S&P Global

Last stock split

26 Apr 2004, 5-for-4 (1.25x)

S&P Global

Valuation Multiples

MultipleLung KeeBasis

P/E (TTM)

n/m (loss)

TTM net loss about HK$29.4m (FY2025 −22.6, less H1 2025 −3.6, plus H1 2026 −10.4)

P/B

0.57x

Equity HK$1,506.8m (30 Jun 2026)

P/S (TTM)

0.72x

TTM revenue about HK$1,199.5m

Enterprise value

About HK$218m

Market cap HK$865m less net cash HK$647m (30 Jun 2026)

EV / Sales (TTM)

0.18x

Computed

EV / EBITDA (TTM, derived)

About 2.0x

TTM derived EBITDA about HK$110.8m

P / FCF (FY2025)

About 5.1x

FCF HK$168.0m

Dividend yield (trailing 12 months paid: HK12 cents + HK8 cents)

About 14.7%

Computed

Net cash per share

About HK$1.02

Computed

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Interim DPS (HK cents)

156558

Final DPS (HK cents)

2065612

Special DPS (HK cents)

000120

Total DPS (HK cents)

3512102320

Basic EPS (HK cents)

36.072.50-11.47-2.16-3.58

Dividends paid, cash flow (HKD Mn)

208.4164.269.563.1164.2

Capital Markets — Moody's / S&P / Fitch ratings

ItemStatus

Moody's / S&P / Fitch ratings

None (unrated)

Debt outstanding

Nil bank borrowings; lease liabilities HK$2.8m (30 Jun 2026)

Debt maturity profile

Not applicable; leases of HK$2.3m current and HK$0.5m non-current

Altman Z-score

4.26 (S&P Global; "safe" zone)

Analyst Conclusions

Management guidance

There is no quantitative guidance. The H1 2026 interim results (21 Aug 2026) describe:

  • a harsh second-half outlook with multiple downside risks;

  • continued pressure on Chinese exports from tariffs and technology controls;

  • expected support from domestic stimulus and from the policy campaign against involutionary competition;

  • a commitment to improve production efficiency in plastic and die-casting moulds, use intelligent production, and control raw-material and operating costs;

  • a cautious and pragmatic posture.

Consensus growth expectations

Not available (no published estimates).

Analyst run-rate observation, not a forecast:

  • H1 2026 revenue of HK$568m annualises to about HK$1.14bn, below the HK$1.32bn achieved in FY2025.

  • H2 has historically been similar to or slightly below H1 (FY2025: H1 HK$689m, H2 HK$631m).

  • Unless demand improves, FY2026 revenue is likely to decline again and the group is likely to report a fourth consecutive annual loss. The H1 2026 loss of HK$10.4m already includes HK$9.0m of disposal gains.

Bull case

  1. Deep value with downside protection. The stock trades at 0.57x book. Net cash of about HK$1.02 per share covers about 75% of the share price. EV is only about HK$218m against about HK$110m of TTM EBITDA and about HK$168m of FY2025 FCF.

  2. Operating leverage on a recovery. The material ratio is the best in five years (34.3% in H1 2026), and employee costs are finally falling (−5.9% in H1 2026). A return to even FY2024 revenue (HK$1.55bn) on today's cost base could restore profitability. FY2021 shows 20%+ EBITDA margins at HK$2.27bn of revenue.

  3. Policy tailwinds and anti-involution. Beijing's push against destructive price competition, together with NEV, AI/robotics and trade-in demand, could restore pricing power for the scale leader. Weaker private competitors without Lung Kee's cash may exit.

Bear case

  1. Structural, not cyclical, decline. PRC revenue has fallen four out of five years, and the FY2024 rebound proved temporary. Export-oriented customers are moving to ASEAN and India, where Lung Kee has a limited footprint. Its "Others" revenue is flat, not growing.

  2. Value-trap dynamics. Controlling-family ownership of about 74% limits activism. The company has made no buybacks despite the stock trading below net-cash-adjusted book. Dividends of HK$164m in FY2025 consumed almost all FCF, and equity has shrunk by HK$765m since FY2021 (to HK$1,507m).

  3. Cash generation is partly non-repeatable. FY2024–FY2025 FCF relied on inventory liquidation (about HK$146m) and capex at about 0.25x depreciation. Once inventory normalises and maintenance capex resumes, FCF could fall toward EBITDA minus capex of about HK$60–80m on current trends, making the 20-cent dividend unsustainable.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Early Jan 2027Possible profit warning or alert for FY2026, the de facto guidance event
Mar 2027FY2026 final results and final dividend decision, a key test of payout sustainability
OngoingMonthly China data on appliance, NEV and electronics output; trade-in programme extensions
OngoingUS-China tariff negotiations; Middle East conflict and logistics costs
OngoingEvidence of PRC price recovery under anti-involution policy
OngoingInventory level (HK$302m at June 2026) and capex trajectory
May 2027AGM: buyback mandate (watch for first use), director re-elections, board refresh (INED tenure)
Any timeFounder or family share dealings, or any privatisation proposal, given the discount to net assets

Concluding analyst verdict

Lung Kee Group is a well-capitalised industry leader caught in a prolonged downturn that increasingly looks structural. Its LKM brand, scale and catalogue standards remain real assets. The company was the first in Hong Kong to put CNC machining into mould bases, it calls itself the leader of China's mould base industry, and its customer base is so fragmented that no buyer reaches 10% of sales.

None of that has protected the income statement. Revenue fell from HK$2.27bn in FY2021 to HK$1.32bn in FY2025 and is falling at a 17.5% annual pace in H1 2026. The group has lost money in each of the last three full years and in H1 2026, because a largely fixed workforce and depreciation base cannot flex down with volumes.

The balance sheet tells a very different story. With HK$650m of cash, no debt and FCF of HK$168–191m in each of the last two years, Lung Kee is valued by the market at roughly 2x trailing EBITDA on an enterprise basis and 0.57x book. Shareholders have been rewarded with a trailing yield near 15%.

The core debate is whether this is a value opportunity or a value trap. The evidence leans toward a slow-liquidating asset base: capex at a quarter of depreciation, shrinking PPE and inventory, and dividends that match FCF. That model rewards patient income investors for some time. It does not, on its own, create growth.

Re-rating would need one of three things:

  • a demand-led recovery in Chinese tooling, helped by anti-involution pricing;

  • a decisive capital allocation move, such as buybacks at a deep discount, an ASEAN or India expansion, or consolidation of weaker competitors;

  • a corporate action by the controlling family.

Absent these, we would characterise the shares as a defensive, high-yield, net-cash holding with poor earnings momentum. The main monitorables are dividend coverage and the trajectory of PRC demand.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure on boardBackground / prior rolesEducationAge (approx.)

Mr. Siu Tit Lung (邵鐵龍)

Executive Director, Chairman; co-founder

Since Dec 1992 (co-founded business in 1975)

Co-founder of Lung Kee Metal; elder brother of Siu Yuk Lung; director of Pan Island Investments, Rickdee Investments and Robin Hill Investments (substantial shareholders)

—

About 76 (aged 56 per 2006 Annual Report)

Mr. Siu Yuk Lung (邵玉龍)

Executive Director, Managing Director (chief executive role); co-founder

Since Dec 1992

Co-founder; younger brother of the Chairman; member of the Hong Kong Mould Association; director of Pan Island, Rickdee and Robin Hill

—

About 73 (aged 53 per 2006 Annual Report)

Mr. Wai Lung Shing (韋龍城), William

Executive Director, Finance Director and Company Secretary

Since Dec 1992

Long-serving finance head; member of the Institute of Chartered Accountants in England & Wales and the Chinese Institute of Certified Public Accountants

MBA, University of Warwick; undergraduate studies at The Hong Kong Polytechnic University

About 65 (aged 45 per 2006 Annual Report)

Mr. Ting Chung Ho (丁宗浩)

Executive Director

—

Operational executive

——

Mr. Siu Yuk Tung, Ivan (邵旭桐)

Executive Director

————

Mr. Siu Yu Hang, Leo (邵宇衡)

Executive Director

————

Dr. Lee Tat Yee (李達義)

Independent Non-Executive Director; Chair of Remuneration Committee

On board since at least 2004 (listed in FY2003 Annual Report), i.e. 20+ years

Not detailed in sources reviewed

Doctorate (title "Dr."); details not disclosed

—

Mr. Wong Hak Kun (王克勤)

Independent Non-Executive Director; Chair of Audit Committee

—

Not detailed in sources reviewed

——

Ms. He Lamei (何腊梅)

Independent Non-Executive Director; Chair of Nomination Committee

—

Not detailed in sources reviewed

——

“—” = not publicly disclosed.

Directors' Remuneration

CommitteeChairMembers

Audit Committee

Mr. Wong Hak Kun

Dr. Lee Tat Yee, Ms. He Lamei

Remuneration Committee

Dr. Lee Tat Yee

Mr. Wong Hak Kun, Ms. He Lamei

Nomination Committee

Ms. He Lamei

Dr. Lee Tat Yee, Mr. Wong Hak Kun

Governance Overview

AttributeStatus

Board size

9 (6 executive, 3 INED)

Independence

3 of 9 (33.3%), exactly the HKEX minimum of one-third

Chair / CEO separation

Formally separate (Chairman Siu Tit Lung; MD Siu Yuk Lung), but held by co-founder brothers who jointly control the majority shareholder. Effective separation is limited

Gender diversity

1 woman of 9 directors (11%)

Family representation

4 of 9 directors are Siu family members

Corporate Governance Code compliance

Company states full compliance with all code provisions of Appendix C1 for FY2023, FY2025 and H1 2026

INED tenure

Dr. Lee Tat Yee has served more than 20 years. HKEX's Corporate Governance Code review (concluded Dec 2024) introduces a cap on INED tenure phased in over the coming years, which may require board refreshment

Board of Directors by Director

DirectorRoleFees (HKD K)Salary & benefits (HKD K)Retirement (HKD K)Total (HKD K)

Siu Tit Lung

Chairman

08,4009249,324

Siu Yuk Lung

Managing Director

08,4009249,324

Wai Lung Shing

Finance Director

02,6402902,930

Ting Chung Ho

ED

02,5692832,852

Siu Yuk Tung, Ivan

ED

01,9202112,131

Siu Yu Hang, Leo

ED

01,920181,938

Lee Tat Yee

INED

43600436

Lee Joo Hai

INED (resigned 31 Dec 2024)

43600436

Wong Hak Kun

INED

45200452

He Lamei

INED

38900389

Total board

—

1713

25849

2650

30212

Directors' Remuneration (Annual)

MetricFY2019FY2020FY2021FY2022FY2023

Total board emoluments (HKD K)

44,75447,85952,46430,00030,212

Of which bonus (HKD K)

14,90018,10022,7001,5000

Board & Management Changes

DateChange

31 Dec 2024

Resignation of INED Mr. Lee Joo Hai; board committees reconstituted; board reduced from 10 to 9

2023–2024

Share options granted (about 2.43m in 2023; further grant 27 Sep 2024)

No change

No change to Chairman, MD or Finance Director in the last five years

Major Shareholders

HolderSharesApprox. stake (%)NatureSource

Pan Island Investments Limited

366,210,93757.8

Wholly owned by a discretionary trust for Siu family members (other than the founders themselves)

Simply Wall St; FY2006/2007 reports (structure)

David Webb (and associates)

37,938,4986.0

Long-standing minority investor

Simply Wall St (secondary)

Siu Tit Lung (personal, incl. joint holding with Siu Yuk Lung)

35,851,2885.65

Founder

MarketScreener / Zonebourse, as at 30 Sep 2025

Siu Yuk Lung (personal, incl. joint holding)

Approx. similar to Chairman (overlapping joint holding)

—

Founder

Secondary

Rickdee Investments Limited

——

Discretionary trust (family of Siu Tit Lung)

2007 Interim Report (structure)

Robin Hill Investments Limited

——

Discretionary trust (family of Siu Yuk Lung)

2007 Interim Report (structure)

Wai Lung Shing

3,843,7500.61

Executive director

MarketScreener, as at 30 Jun 2025

Institutions (aggregate)

—

About 2.6–5.2

Data providers differ

S&P Global / Simply Wall St

Free float

About 162m shares

About 25.6

Per S&P Global

StockAnalysis.com

Competitive Landscape

Key Competitors

#CompetitorCountryRelevant businessRelative positioning vs Lung Kee
1

HASCO Hasenclever GmbH

Germany

Standard mould bases and components, hot runners

Premium global standard; stronger in Europe; higher price point

2

Meusburger Georg GmbH

Austria

Standard mould bases, plates, components

Premium European standard; expanding in Asia; strong e-commerce

3

DME (Hillenbrand / Milacron group)

USA

Mould bases, components, hot runners

Leading North American standard; part of a large diversified group

4

Futaba Corporation (mould & die components business)

Japan

Mould bases and die sets

Japanese standard; competes directly in Japan and with Japanese OEM tooling in China and ASEAN

5

MISUMI Group

Japan

Catalogue configurable mould and die components

Dominant in components through digital ordering; less focused on full mould bases

6

Punch Industry Co., Ltd.

Japan

Mould and die components (with China plants)

Component specialist in China and Japan

7

Progressive Components

USA

Mould components and monitoring

Niche premium components

8

Mainland Chinese mould base makers (numerous private firms in the Pearl River Delta, Ningbo/Zhejiang and Kunshan/Jiangsu clusters)

PRC

Standard and custom mould bases

Main source of price pressure; lower cost, lower brand equity

9

Taiwanese mould base makers

Taiwan / PRC

Mould bases

Compete for Taiwanese-owned factories in China

10

In-house tool rooms of large OEMs

Various

Self-supply of bases

Substitution risk

Competitor Detail

MetricLung Kee (FY2025)

Revenue

HK$1,319.9m

Revenue growth

-15.0%

Net margin

-1.7%

EBITDA margin (derived)

9.5%

Balance sheet

Net cash HK$584m; no debt

Recent Developments

Lung Kee is a low-disclosure micro-cap. Earlier entries back to late 2024 are added for context.

Product launches, contract wins, litigation, regulatory actions and layoff announcements: none publicly announced in the period.

Company Snapshot

$169.4M

Revenue

2,700

Employees

1975

Founded

Bermuda

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. HK$649.7m cash, zero borrowings and HK$2.8m lease liabilities at 30 Jun 2026. Net cash covers about 75% of the HK$865m market capitalisation. [H1 2026 Interim Results]
  • Strong free cash flow despite losses. FCF of HK$190.8m (FY2024) and HK$168.0m (FY2025), driven by HK$159m of annual depreciation and inventory release. [S&P Global data]
  • Improving material efficiency. The raw-material ratio fell from 43.8% (FY2023) to 35.7% (FY2025) and 34.3% (H1 2026), helped by more machining services and lower steel purchase prices. [FY2025 and H1 2026 results]
  • Customer diversification and credit quality. No customer above 10% of revenue in any period reviewed. Trade receivables over 90 days were only HK$3.9m (FY2025). [FY2025 Final Results]
  • Brand leadership. First Hong Kong mould base maker to adopt CNC; self-described leader of China's mould base industry; LKM catalogue standards widely adopted. [Company profile]
  • Consistent shareholder returns. Dividends were paid every year, including loss years: 10 cents (FY2023), 23 cents including a 12-cent special (FY2024) and 20 cents (FY2025). [Results announcements]

Weaknesses

  • Three consecutive annual losses: HK$72.4m (FY2023), HK$13.7m (FY2024), HK$22.6m (FY2025), plus HK$10.4m in H1 2026. [Results announcements]
  • Shrinking top line. Revenue CAGR of −12.7% for FY2021–FY2025; H1 2026 revenue down a further 17.5%. [Results announcements]
  • Fixed-cost rigidity. Employee costs of HK$421m in FY2025 were nearly flat since FY2023, while revenue fell. The employee-cost ratio is 31.9%. [FY2025 Final Results]
  • High PRC dependence. 85.7% of FY2025 revenue and 83.9% of H1 2026 revenue came from PRC deliveries. [Results announcements]
  • Under-investment. Capex/depreciation of 0.22x (FY2024) and 0.26x (FY2025); PPE down 42% since FY2022. [Results; S&P Global]
  • Thin disclosure. No product, region (beyond PRC/Others), R&D or KPI breakdown; no guidance; no analyst coverage with estimates. [Results announcements; Simply Wall St]

Opportunities

  • NEV and die-casting tooling. Management is prioritising die-casting technology (FY2025 and H1 2026 outlooks) as NEV structural parts proliferate.
  • Policy stimulus. Extended trade-in programmes and support for smart appliances, high-tech electronics, AI/robotics and low-altitude economy products (H1 2026 outlook).
  • Anti-involution measures. Beijing's push to regulate destructive price competition could restore pricing for the market leader (H1 2026 outlook).
  • Following customers offshore. Diversification of export customers into ASEAN, Vietnam and India (FY2025 outlook). The existing Malaysian plant and Japanese base could be leveraged.
  • Capital redeployment. HK$650m of idle cash could fund bolt-on acquisitions of distressed Chinese competitors, an ASEAN plant, buybacks at about 0.57x book, or further special dividends.
  • Operating leverage on recovery. At FY2021 revenue (HK$2.27bn), the group earned an EBITDA margin of 20.8% and ROIC of about 16%. A volume recovery would flow through a now-automated, leaner cost base.

Threats

  • Structural decline in China consumer-durables tooling due to the protracted property downturn (cited in every results announcement from FY2022 to H1 2026).
  • US tariffs and technology controls suppressing China's export manufacturing (FY2025 and H1 2026 results).
  • Price competition from lower-cost Chinese rivals; the FY2023 price cuts and FY2025 failure to raise prices show the risk.
  • Geopolitical and energy shocks. The 2026 Middle East conflict disrupted logistics and energy supply chains (H1 2026 results).
  • Hong Kong property value decline reduces investment property values (cumulative HK$28.5m of revaluation losses in FY2023–FY2025 plus HK$4.3m in H1 2026).
  • RMB currency risk. Translation losses of HK$136.3m in FY2022 and HK$44.4m in FY2023 hit equity; substantially all assets are RMB-based.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Sep 2024Grant of share optionsRetention incentive; small dilution potential
31 Dec 2024INED Lee Joo Hai resigns; committees reconstitutedBoard shrinks to nine; INEDs at the one-third minimum
31 Dec 2024Bermuda principal registrar changed to ApplebyAdministrative
6 Jan 2025Profit alert: reduced loss for FY2024Signals stabilisation after the FY2023 loss
6 Mar 2025Board meeting notice for FY2024 resultsRoutine
21 Mar 2025FY2024 results: revenue HK$1,553.2m (+7.2%), loss HK$13.7m; final dividend HK6 cents plus special HK12 centsSpecial dividend signals excess capital
3 Apr 2025Notice of AGMRoutine
19 May 2025AGM: all resolutions passed (accounts, dividends, director re-elections, issuance and buyback mandates)Buyback mandate renewed (unused)
9 Jun 2025FY2024 final and special dividends paid (HK$113.7m total)Major cash return
Jul 2025Positive profit alert: H1 2025 loss of no more than HK$5m (H1 2024: HK$24m), on higher selling prices, more machining and lower raw-material costsMargin inflection
7 Aug 2025Board meeting notice for interim resultsRoutine
22 Aug 2025H1 2025 results: revenue HK$688.7m (−12.3%); loss HK$3.6m (−85.1%); interim dividend raised to HK8 cents (H1 2024: HK5 cents)Dividend increase despite revenue decline
23 Sep 2025H1 2025 interim dividend paid (HK$50.5m)Cash return
c. 30 Sep 2025Founders reported to increase interests (about 6.49m shares each; per aggregator)Insider buying signal (if confirmed)
5 Jan 2026Profit warning: FY2025 loss to increaseRecovery stalls
20 Mar 2026FY2025 results: revenue HK$1,319.9m (−15.0%); loss HK$22.6m; final dividend HK12 cents; full CG Code complianceRevenue at multi-year low; payout maintained
18 May 2026AGM (FY2025)–
22 May 2026Shares go ex-dividend for FY2025 finalRoutine
9 Jun 2026FY2025 final dividend paid (HK$76.1m)Cash return
7 Jul 2026Profit warning for H1 2026 (larger loss)Deterioration flagged
6 Aug 2026Board meeting notice for interim resultsRoutine
21 Aug 2026H1 2026 results: revenue HK$568.3m (−17.5%); loss HK$10.4m; interim dividend HK8 cents maintained; headcount about 2,700Continued decline; payout held
26 Aug 20262026 Interim Report published (Deloitte review report dated 21 Aug 2026)Routine
9 Sep 2026Record date for H1 2026 interim dividendRoutine
c. 22 Sep 2026H1 2026 interim dividend payable (HK$50.7m)Cash return

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue fell from HKD 2,273.4 Mn in FY2021 to HKD 1,319.9 Mn in FY2025.
Lung Kee (Bermuda) Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue2,273.41,601.41,449.31,553.21,319.9
Cost of inventories expensed1,656.21,346.81,336.11,330.51,135
Gross profit617.2254.6113.3222.7184.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Lung Kee Group Holdings Limited — Interim Results Announcement for the six months ended 30 June 2026 (21 Aug 2026) (www1.hkexnews.hk)
  2. Lung Kee Group Holdings Limited — 2026 Interim Report (26 Aug 2026) (www1.hkexnews.hk)
  3. Lung Kee Group Holdings Limited — Date of Board Meeting (6 Aug 2026) (www1.hkexnews.hk)
  4. Lung Kee Group Holdings Limited — Final Results for the year ended 31 December 2025 (20 Mar 2026) (cre8ir.com)
  5. Lung Kee Group Holdings Limited — Interim Results Announcement for the six months ended 30 June 2025 (22 Aug 2025) (www1.hkexnews.hk)
  6. Lung Kee Group Holdings Limited — Interim Results Announcement H1 2024 (23 Aug 2024) (www1.hkexnews.hk)
  7. Lung Kee (Bermuda) Holdings Limited — Final Results for the year ended 31 December 2023 (22 Mar 2024) (www1.hkexnews.hk)
  8. Lung Kee (Bermuda) Holdings Limited — Profit Warning (5 Jan 2024) (www1.hkexnews.hk)
  9. Lung Kee (Bermuda) Holdings Limited — 2023 Annual Report (hkexnews.hk)
  10. Lung Kee (Bermuda) Holdings Limited — Final Results for the year ended 31 December 2022 (24 Mar 2023) (www1.hkexnews.hk)
  11. Lung Kee (Bermuda) Holdings Limited — 2022 Annual Report (hkexnews.hk)
  12. List of Directors and their Role and Function (1 Jan 2025) (cre8ir.com)
  13. Corporate Information (irasia) (irasia.com)
  14. Company Profile (irasia) (irasia.com)
  15. Announcement indices (irasia) · irasia.com
  16. Historic: FY2003 Annual Report sections (EWP106, EWP108, EWP119); FY2002/03 Annual Report (EWP105, EWP106); FY2006 Annual Report Directors' Report (EWF109); 2007 Interim Report (E110); FY2005 results announcement; irasia five-year summary FY1995–FY1999
  17. S&P Global Market Intelligence via StockAnalysis.com — cash flow, statistics and price (stockanalysis.com)
  18. Webb-site.com — director pay FY2016–FY2023 (webb-site.com)
  19. Simply Wall St — ownership, company information (simplywall.st)
  20. MarketScreener / Zonebourse — insider holdings and director profiles
  21. TipRanks — revenue history, profit alert summaries, AGM summaries
  22. moomoo — company profile, news feed (SGX delisting timeline, name change)
  23. Google Finance — trading range (Dec 2025)
  24. Asia Pacific Metalworking Equipment News — LKM interview (capacity, standardisation)
  25. Morningstar — business description

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.